Why Do Some People Get Fewer Side Effects on Dutasteride Than Finasteride?
Published by AmpleLab Research
It comes up constantly in hair loss communities: someone had a rough time on finasteride, switched to dutasteride, and felt noticeably better, despite dutasteride suppressing DHT more completely than finasteride does. On paper that's backwards. A stronger drug producing fewer side effects in the same person isn't what you'd predict from DHT suppression alone, and the usual explanations offered for it tend to be vague or hand-wavy.
The phenomenon is reported clinically, and there's genuine, peer-reviewed research that provides a plausible mechanistic explanation for why individual responses to the two drugs can differ. That research doesn't prove these specific variants cause the side-effect differences people report; it establishes a real, biologically grounded reason such differences are plausible, which is a more specific and more interesting story than most of what circulates about it. This article covers general side-effect tolerability, using pharmacogenetic research on how the two drugs bind the enzyme itself. For the specific question of mood and depression, which involves a different body of evidence entirely, see our article on finasteride, dutasteride, and depression risk, which looks at population-level pharmacovigilance and cohort data rather than individual enzyme genetics.
One Mechanistic Explanation: Your Enzyme Isn't Identical to Everyone Else's
The gene encoding type II 5-alpha reductase, SRD5A2, isn't identical from person to person. Multiple naturally occurring variants exist in the human population, and a study specifically comparing how finasteride and dutasteride interact with these variants found something directly relevant to this question.
This pharmacogenetic analysis directly compared how finasteride and dutasteride inhibit different naturally occurring SRD5A2 enzyme variants. Several known SRD5A2 variants showed increased enzyme activity and reduced inhibition by finasteride specifically, meaning finasteride binds and blocks the enzyme less effectively in people carrying those variants. Dutasteride, by contrast, showed significantly lower inhibition constants (meaning stronger, more consistent inhibition) across nearly all the SRD5A2 variants tested, and displayed considerably less pharmacogenetic variation overall than finasteride did.
Put plainly: some people's specific version of the type II enzyme may be a less favourable match for finasteride's binding chemistry, in a way it generally isn't for dutasteride's. This doesn't map cleanly onto "therefore finasteride causes worse side effects in these people", the relationship between enzyme inhibition and any individual side effect is more complicated than that, and this study measured enzyme kinetics in a lab setting, not clinical side effect outcomes directly. But it establishes a real, specific, measurable reason why finasteride's inhibition of SRD5A2 can differ between individuals, in a way dutasteride appears comparatively protected against.
Dutasteride Has Its Own Genetic Variation Story
Dutasteride isn't immune to individual variation; it just varies for different reasons, tied to the additional type I enzyme it targets that finasteride largely leaves alone.
Forty-two men treated with dutasteride for six months were genotyped and analysed for genetic variants associated with treatment response. The strongest associations were in DHRS9 and CYP26B1, genes not directly part of the androgen pathway, alongside suggestive associations in SRD5A1 (the gene for type I 5-alpha reductase, dutasteride's additional target), ESR1 (oestrogen receptor), and CYP19A1 (aromatase). Notably, SRD5A2 variants were not associated with dutasteride response in this study, consistent with the Makridakis finding that dutasteride's inhibition is comparatively robust across SRD5A2 variation.
This study measured treatment response (hair regrowth), not side effects specifically, and the authors themselves note that having a favourable variant didn't guarantee a good response, and some patients with the same "positive" genetic markers still responded poorly. It's suggestive, small-scale, hypothesis-generating research, not a validated predictive model. What it does suggest is that individual variation in dutasteride response may involve a broader set of genes than the SRD5A2 variation highlighted for finasteride, involving oestrogen and vitamin A metabolism pathways alongside the androgen ones, which points to a genuinely different genetic story from finasteride's more narrowly SRD5A2-centred variation.
The Other Genuine Differences, Covered Elsewhere
Pharmacogenetics isn't the only real factor at play, and we've covered the others in depth in our finasteride vs dutasteride comparison rather than repeating them fully here: the substantial difference in overall DHT suppression (roughly 65-70% for finasteride versus 90%+ for dutasteride), the possible role of neurosteroid metabolism given dutasteride's additional type I inhibition, and dutasteride's much longer half-life, which affects how quickly any side effects resolve after stopping either drug, not why they occur in the first place.
None of these factors, including the genetics covered above, fully explains why any specific individual responds the way they do. They're pieces of a real, still-incomplete picture, not a solved equation.
What This Means in Practice
Commercial genetic tests are already being marketed around these kinds of pharmacogenetic claims, suggesting they can predict individual response to finasteride or dutasteride based on variants like the ones covered above. The research behind these associations is real but early: small sample sizes, associations rather than confirmed causal mechanisms, and, in the case of the dutasteride response genetics, findings that didn't hold for every patient carrying the relevant variant. Genetics likely does influence why you'd respond differently to these two drugs; that's not currently the same as saying a commercial test can reliably tell you which one to choose in advance.
In practice, this means the empirical approach most prescribers already use, starting with one drug, monitoring the response over several months, and switching if needed, remains the practical path, not because the underlying genetics aren't real, but because there isn't yet a validated test that reliably tells you the answer before you start. If finasteride hasn't worked for you or caused side effects, there's a genuine, mechanistically grounded reason dutasteride might behave differently in your specific case, not because it's simply "the stronger option that happens to suit more people," but because genetic variation in SRD5A2 can affect how the two drugs interact with the enzyme.
Frequently Asked Questions
Is dutasteride simply "gentler" than finasteride for everyone?
No. Dutasteride suppresses DHT more completely than finasteride, and some individual trials report a somewhat higher rate of certain sexual side effects on dutasteride overall. The genetic variation covered here explains why specific individuals can respond in the opposite direction to what the average trial data would predict, not that dutasteride is generally the milder option.
Can I get a genetic test to find out which drug will suit me?
Tests exist, but the research they're based on is still early-stage: small studies, associations rather than confirmed prediction, and inconsistent results even among patients sharing the same genetic marker. We wouldn't currently treat a result from one of these tests as a reliable basis for choosing between the two drugs without discussing it with a prescriber.
If finasteride gave me side effects, does that mean dutasteride definitely won't?
No. The genetics covered here explain why the two drugs can behave differently in the same person, not that switching guarantees a better outcome. Some people have side effects on both, some on neither, and some (as covered) find one clearly more tolerable than the other. It genuinely varies.
Does this pharmacogenetic difference also explain why some people don't respond to finasteride for hair growth, not just side effects?
Plausibly, at least in part. If a particular SRD5A2 variant reduces how effectively finasteride inhibits the enzyme, that could potentially reduce both the treatment effect and any DHT-related side effects together, not one without the other. This hasn't been directly confirmed by linking the specific enzyme-binding variants to real-world treatment outcomes in a large study, so it's a reasonable inference from the mechanism rather than a demonstrated finding.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. Finasteride and dutasteride are prescription medications; decisions about starting, stopping, or switching between them should be made with a GP or dermatologist. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.